OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC

Patients with advanced, pretreated HCC receiving pembrolizumab in a phase 3 trial did not experience OS or PFS benefits compared with those receiving placebo.

from Latest articles from Cancer Therapy Advisor Gastrointestinal Cancers https://ift.tt/2tFZ0GN